Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases

Phytomedicine

Volumn 16, Issue 2-3, 2009, Pages 111-117

  Feher, Gergely ^a   Koltai, Katalin ^a   Kesmarky, Gabor ^a   Horvath, Beata ^a   Toth, Kalman ^a   Komoly, Samuel ^a   Szapary, Laszlo ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Chronic cerebrovascular diseases; Ethylapovincaminate; Hemorheological parameters; Parenteral and oral administration; Vinpocetine

Indexed keywords

FIBRINOGEN; PLACEBO; VINPOCETINE;

ADULT; AGED; ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; BRAIN ISCHEMIA; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MEGADOSE; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMATOCRIT; HEMODILUTION; HUMAN; HUMAN CELL; MALE; PLASMA VISCOSITY; PRIORITY JOURNAL; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; AGED; BLOOD VISCOSITY; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; FEMALE; FIBRINOGEN; HEMATOCRIT; HEMORHEOLOGY; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PHYTOTHERAPY; PILOT PROJECTS; PLATELET AGGREGATION; SINGLE-BLIND METHOD; VINCA; VINCA ALKALOIDS;

EID: 59849128362     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2008.10.014     Document Type: Article

References (34)

1. Adams, H.P., Biller, J., 1996. Vascular disease of the nervous system, in: A. Ischemic cerebrovascular diseases. In: Bradley, W.G., Daroff, R.B., Fenichel, G.M. Marsden, CD. (Eds.), Neurology in Clinical Practice, second edition, vol. II. Newton, Butterworth-Heinemann, pp. 993-1031.
2. Bonoczk P., Gulyas B., and Adam-Vizi V. Role of sodium channel inhibition in neuroprotection: effect of vinpocetin. Brain Res. Bull. 53 (2000) 245-254
3. Bonoczk P., Panczel G., and Nagy Z. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. Eur. J. Ultrasound 15 (2002) 85-91
4. Cavestri R., Radice L., Ferrarini F., Longhini M., and Longhini E. Influence of erythrocyte aggregability and plasma fibrinogen concentration on CBF with aging. Acta Neurol. Scand. 85 (1992) 292-298
5. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 17 (1957) 237-246
6. Elwan O., al-Ashmawy S., el-Karaksy S., and Hassan A.A. Hemorheology, stroke and the elderly. J. Neurol. Sci. 101 (1991) 157-162
7. Ernst E. Fibrinogen: its emerging role as a cardiovascular risk factor. Angiol 45 (1994) 87-93
8. Ernst E., Resch K.L., Matrai A., Buhl M., Schlosser P., and Paulsen H.F. Impaired blood rheology: risk factor after stroke?. J. Intern. Med. 229 (1991) 457-462
9. Feigin V.L., Doronin B.M., Popova T.F., Gribatcheva E.V., and Tchervov D.V. Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur. J. Neurol. 8 (2001) 81-85
10. Fieschi C., Agnoli A., Battistini N., Bozzao L., and Prencipe K. Derangement of regional cerebral blood flow and of its regulatory mechanisms in acute cerebrovascular lesions. Neurology 18 (1968) 1166-1179
11. Fisher M., and Meiselman H.J. Hemorheological factors in cerebral ischemia. Stroke 22 (1991) 1164-1169
12. Grotta J.C., Ackerman R., Correia J., Fallick G., and Chang J. Whole blood viscosity parameters and cerebral blood flow. Stroke 13 (1982) 296-301
13. Harrison M.J., Pollock S., Kendall B.E., and Marshall J. Effect of haematocrit on carotid stenosis and cerebral infarction. Lancet 8238 (1981) 114-115
14. Hayakawa M. Effect of vinpocetin on red blood cell deformability in stroke patients. Arzneim.-Forsch./Drug Res. 42 (1992) 425-427
15. Horvath B., Marton Zs., Halmosi R., Alexy T., Szapary L., Vekasi J., Biro Zs., Habon T., Kesmarky G., and Toth K. In vitro antioxidant properties of pentoxiphyllin, piracetam, and vinpocetine. Clin. Neuropharm. 25 (2002) 37-42
16. Kesmarky G., Toth K., Habon L., Vajda G., and Juricskay I. Hemorheological parameters in coronary artery disease. Clin. Hemorheol. Microcirc. 18 (1998) 245-251
17. Klose H.J., Volger E., Brechtelsbauer H., Heinich L., and Schmid-Schonbein H. Microrheology and light transmission of blood. Pflugers Arch. 333 (1972) 126-139
18. Koenig W., and Ernst E. The possible role of hemorheology in atherothrombogenesis. Atherosclerosis 94 (1992) 93-107
19. Kuzuya F., Osawa M., and Maruyama S. Effects of vinpocetine on blood viscosity and platelet aggregability. Today's Therap. Trends 1 (1985) 21-29
20. Lorincz C., Szasz K., and Kisfaludy L. The synthesis of ethyl apovincaminate. Arzneim.-Forsch. Drug Res. 26 (1976) 1907-1908
21. Lowe G.D.O., Lee A.J., Rumley A., Price J.F., and Fowkes F.G. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br. J. Haematol. 96 (1997) 168-173
22. Mchedlishvili G., Shakarishvili R., and Momtselidze M. Elaborated-'Georgian index' of erythrocyte aggregability characterizing the microrheological disorders associated wit brain infarct. Clin. Hemorheol. 15 (1995) 783-793
23. Myazaki M. Correlation between cerebral circulation and intellectual impairment in patients with "aging brain", and the effects of vinpocetine on cerebral circulation. Drug Dev. Res. 14 (1988) 199-204
24. Nagy Z., Vargha P., Kovacs L., and Bonoczk P. Metaanalysis of Cavinton trials (in Hungarian). Praxis 7 (1998) 63-68
25. Osawa M., and Maruyama S. Effects of TVC-3B (Vinpocetine) on blood viscosity is ischemic cerebrovascular diseases. Ther. Hung. 33 (1985) 7-12
26. Ott N.E., Fazekas F., Tschinkel M., Bertha G., and Lechner H. Rheological aspects of cerebrovascular disease. Eur. Neurol. 22 (1983) 35-37
27. Schneider R., Kiesewetter H., F Jung., Bruckmann H., and Hacke W. Haemorheology and ischemic brain infarct: what is established?. Nervenarzt 57 (1986) 447-454
28. Szabo L., Sapi J., Kalaus Gy., Argay G., Kalman A., Baitz-Gacs E., Tamas J., and Szantay C. New route to the stereoselective synthesis of (b)-vincamine, (b)-vincamone, and (b)-apovincaminic acid esters. Tetrahedron Lett. 316 (1983) 629-638
29. Szakall S., Boros I., Balkay L., Emri M., Fekete I., Kerenyi L., Lehel S., Marian T., Molnar T., Varga J., Galuska L., Tron L., Bereczki D., Csiba L., and Gulyas B. Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. J. Neuroimag. 8 (1998) 197-204
30. Szapary L., Horvath B., Alexy T., Marton Zs., Kesmarky G., Szots M., Nagy F., Czopf J., and Toth K. Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease. Orv. Hetil. 144 (2003) 973-978
31. Szapary L., Horvath B., Marton Zs., Alexy T., Demeter N., Szots M., Klabuzai A., Kesmarky G., Juricskay I., Gaal V., Czopf J., and Toth K. Hemorheological disturbances in patients with chronic cerebrovascular diseases. Clin. Hemorheol. Microcirc. 31 (2004) 1-9
32. Tanahashi N., Gotoh F., Tomita M., Shinohara T., Terayama Y., Mihara B., Ohta K., and Nara M. Enhanced erythrocyte aggregability in occlusive cerebrovascular disease. Stroke 20 (1989) 1202-1207
33. Tanahashi N., Tomita M., Kobari M., Takeda H., Yokoyama M., and Fukuuchi Y. Aspirin improves the enhanced erythrocyte aggregability in patients with cerebral infarction. J. Neurol. Sci. 139 (1996) 137-140
34. Tsuda Y., Satoh K., Kitadai M., and Takahashi T. Hemorheologic profiles of plasma fibrinogen and blood viscosity from silent to acute and chronic cerebral infarctions. J. Neurol. Sci. 147 (1997) 49-54